CRISPR Therapeutics AG (NASDAQ: CRSP) is 17.29% higher on its value in year-to-date trading and has touched a low of $30.04 and a high of $71.13 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRSP stock was last observed hovering at around $65.33 in the last trading session, with the day’s gains setting it 0.6%.
Currently trading at $65.93, the stock is 21.28% and 45.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.19 million and changing 0.92% at the moment leaves the stock 50.37% off its SMA200. CRSP registered 67.51% gain for a year compared to 6-month gain of 62.67%. The firm has a 50-day simple moving average (SMA 50) of $45.3445 and a 200-day simple moving average (SMA200) of $43.846474.
The stock witnessed a 48.99% loss in the last 1 month and extending the period to 3 months gives it a 74.33%, and is 25.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.54% over the week and 6.35% over the month.
CRISPR Therapeutics AG (CRSP) has around 393 employees, a market worth around $5.69B and $37.67M in sales. Profit margin for the company is -1023.64%. Distance from 52-week low is 119.47% and -7.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.99%).
The EPS is expected to shrink by -26.39% this year.
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
525.0 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 84.24% of the company’s shares. The shares outstanding are 86.36M, and float is at 81.79M with Short Float at 31.23%. Institutions hold 82.82% of the Float.
The top institutional shareholder in the company is CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares valued at $424.8 million. The investor’s holdings represent 9.2619% of the CRSP Shares outstanding. As of 2024-06-30, the second largest holder is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares valued at $420.12 million to account for 9.1597 of the shares outstanding. The other top investors are SUMITOMO MITSUI TRUST HOLDINGS, INC. which holds 3.15 million shares representing 3.7111% and valued at over $170.21 million, while NIKKO ASSET MANAGEMENT AMERICAS, INC. holds 3.7111 of the shares totaling 3.15 million with a market value of $169.99 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
The most recent transaction is an insider purchase by George Simeon, the company’s Director. SEC filings show that George Simeon bought 989,812 shares of the company’s common stock on Jul 16 ’25 at a price of $52.03 per share for a total of $51.5 million. Following the purchase, the insider now owns 1.73 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on May 29 ’25 that Patel Naimish (Chief Medical Officer) sold a total of 3,932 shares of the company’s common stock. The trade occurred on May 29 ’25 and was made at $35.94 per share for $0.14 million. Following the transaction, the insider now directly holds 6068.0 shares of the CRSP stock.
Still, SEC filings show that on Mar 21 ’25, Kulkarni Samarth (Chief Executive Officer) disposed off 10,031 shares at an average price of $41.23 for $0.41 million. The insider now directly holds 195,085 shares of CRISPR Therapeutics AG (CRSP).
